Charles River Laboratories International, Inc.
CRL- Exchange
- NYSE
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001100682
In the last 90 days, Charles River Laboratories International, Inc. insiders filed 0 open-market purchases and 9 sales; 569 institutions reported holding it in 13F filings for Q2 2026, worth $12.9B in total; Harris Associates (Oakmark) is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Charles River Laboratories International, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 634
- +24 vs. Q3 2023
- Shares held
- 52.0M
- +210.0K (+0.4%) vs. Q3 2023
- Total value
- $12.3B
- +$2.14B (+21.1%) vs. Q3 2023
- New holders
- 94
- 202 more added
- Sold out
- 70
- 259 more reduced
12 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 569 | $12.9B |
| Q1 2026 | 560 | $9.86B |
| Q4 2025 | 584 | $10.6B |
| Q3 2025 | 556 | $7.92B |
| Q2 2025 | 519 | $7.73B |
| Q1 2025 | 562 | $8.03B |
| Q4 2024 | 636 | $9.78B |
| Q3 2024 | 629 | $10.3B |
| Q2 2024 | 665 | $10.8B |
| Q1 2024 | 675 | $14.1B |
| Q4 2023 | 634 | $12.3B |
| Q3 2023 | 622 | $10.1B |
| Q2 2023 | 613 | $10.7B |
| Q1 2023 | 623 | $10.3B |
| Q4 2022 | 630 | $10.8B |
| Q3 2022 | 583 | $9.91B |
| Q2 2022 | 629 | $10.4B |
| Q1 2022 | 644 | $13.5B |
| Q4 2021 | 708 | $17.8B |
| Q3 2021 | 679 | $19.3B |
| Q2 2021 | 639 | $17.6B |
| Q1 2021 | 562 | $13.7B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Charles River Laboratories International, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cary Street Partner Investment Advisory LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Headinvest, LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| North Star Investment Management Corp. | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Stonebridge Capital Advisors LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Mastrapasqua Asset Management Inc | – | – | – | – | Not filed |
| Community Capital Management, Inc. | – | – | – | – | Not filed |
| First Republic Investment Management, Inc. | – | – | – | – | Not filed |
| Pathstone Family Office, LLC | – | – | – | – | Not filed |
| Advisor Partners II, LLC | – | – | – | – | Not filed |
| Amica Retiree Medical Trust | – | – | – | – | Not filed |
| Icon Wealth Partners, LLC | – | – | – | – | Not filed |
| Column Capital Advisors, LLC | – | – | – | – | Not filed |
| Steward Financial Group LLC | – | – | – | – | Not filed |
| Johnson Midwest Financial, LLC | – | – | – | – | Not filed |
| Sutton Wealth Advisors Inc. | – | – | – | – | Not filed |
| KB Financial Partners, LLC | – | – | – | – | Not filed |